Table 3

Factors at baseline associated with day 45 evaluation for all patients

VariableaData [no., no. (%), or median (range)] for indicated patient(s)Pb
Responder (n = 3)Nonresponder (n = 2)Undetermined (n = 2)
Age (yr)52.1 (15.6–77.8)45.3 (9.8–71.9)31.5 and 63.90.53
Patient risk category0.29
    Allogeneic HSCT10 (33)13 (52)0 (0)
    AL15 (50)7 (28)1 (50)
    Others5 (17)5 (20)1 (50)
EORTC-defined IA0.060
    Proven2 (7)2 (8)0 (0)
    Probable20 (67)22 (88)2 (100)
    Possible8 (27)1 (4)0 (0)
Leukocyte count of <100/mm3 at diagnosis15 (50)12 (48)0 (0)1.00
Receiving corticosteroids11 (37)18 (72)2 (100)0.014
Cumulative dose of prednisone the week before diagnosis (mg/kg of body wt)0.0 (0.0–11.0)7.0 (0.0–28.0)7.0 and 31.00.002
Received immunosuppressive therapy for <1 month8 (27)12 (48)0 (0)0.16
Received antimold therapy for <15 days15 (50)19 (76)0 (0)0.057
Concomitant pulmonary infection8 (27)8 (32)0 (0)0.77
Serum GM antigen value0.4 (0.0–9.3)1.1 (0.1–11.0)0.2 and 4.80.039
    Patient(s) with value of ≥0.514 (47)15 (60)1 (50)0.42
BAL fluid GM antigen value3.4 (0.1–9.8)0.4 (0.0–7.0)0.096
    Patients with value of ≥0.510 (71)8 (53)0.45
Anti-Aspergillus antibody value3.3 (0.1–181.0)3.2 (1.0–108.0)0.2 and 8.10.79
    Patients with value of ≥124 (14)6 (24)0 (0)0.49
Positive mycological examination of respiratory samples13 (57)14 (67)1 (100)0.55
Positive PCR Aspergillus fumigatus2 (9)3 (20)0 (0)0.36
Positive PCR Aspergillus spp13 (57)4 (29)1 (100)0.17
First-line treatment with voriconazole22 (73)20 (80)1 (50)0.75
Halo sign19 (63)14 (56)0 (0)0.59
  • a HSCT, hematopoietic stem cell transplantation; GVHD, graft versus host disease; AL, acute leukemia; CS, corticosteroids; GM, galactomannan.

  • b Fisher's exact test or Wilcoxon rank-sum test for responders versus nonresponders.